Infusion Partners, LLC, Canfield, OH

Is Infusion Partners, LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Infusion Partners, LLC hold a Ohio pharmacy license?

State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks.

Has Infusion Partners, LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Mar 20, 2019), 1 warning letter close-out (Jan 26, 2022), 1 state referral letter (Mar 28, 2019), 1 state handoff letter (Jan 26, 2022) and 1 FMD-145 letter (Jan 26, 2022) for Infusion Partners, LLC. State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Infusion Partners, LLC
Location
Canfield, OH
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
1
Latest action on that page
Jan 26, 2022
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 NAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 10 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Infusion Partners, LLC, a 503A facility, with 5 dated actions.

Document
Jan 26, 2022State handoff letterState Handoff Letter Issued 01/26/2022Not linked by FDA
Jan 26, 2022Warning letter close-outWarning Letter Close Out Issued 01/26/2022Not linked by FDA
Jan 26, 2022FMD-145 letterFMD-145 Letter Issued 01/26/2022Not linked by FDA
Mar 28, 2019State referral letterReferral Letter to the Ohio Board of Pharmacy Issued 03/28/2019FDA copy (archived)
Mar 20, 2019Warning letterWarning Letter (03/20/2019)FDA copy (archived)

A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Infusion Partners, LLC, Canfield, OH (FEI number 3013995728), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Sep 15, 2021No Action Indicated (NAI)Drug Quality Assurance (Drugs)30139957281153907
Jan 26, 2018Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30139957281038731

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 10 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jan 22, 2018 to Jan 26, 2018: 10 observations

Firm on the cover
Infusion Partners, LLC, 4137 Boardman Canfield Rd Ste 1104, Canfield, OH 44406
FEI number
3013995728
Establishment type on the cover
Producer of Sterile Drug Products
FDA district office on the cover
6751 Steger Drive Cincinnati, OH 45237-3097
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

The ISO 5 classified aseptic processing areas had visibly dirty equipment or surface.

Specifically, the HEPA filter guards in all <Redacted B4> ISO 5 laminar airflow hoods had visible whitish and rust-colored residue in and around the holes in the guards. In addition, the <Redacted B4> HEPA filter guards in the ISO 7 cleanroom had flaking paint and rust-colored discoloration on multiple areas of each guard.

Observation 2

Disinfectant contact time (also known as "dwell time") and coverage of the item being disinfected were insufficient to achieve adequate levels of disinfection.

Specifically, the contact time for the <Redacted B4> used as a sporicide in the ISO 5 laminar airflow hoods used to produce sterile drugs and the supporting ISO 7 and ISO 8 cleanrooms is <Redacted B4> minutes, which is estimated by the employee, after which the hood is washed with <Redacted B4> to remove the <Redacted B4>.

Observation 3

Personnel conducted aseptic manipulations and placed equipment/supplies in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.

Specifically,

1) The <Redacted B4> laminar airflow hoods used to produce all non-chemotherapeutic sterile drugs have sagging HEPA guards with <Redacted B4> resulting in approximately 113 ofthe HEPA airflow being blocked by a <Redacted B4> before it can reach the critical area. There are no visually recorded smoke studies to demonstrate that the airflow is not interrupted by these obstacles.

2) There are no velocity measurements for airflow in the ISO 7 cleanroom or the ISO 5 laminar airflow hoods to show that lSO 7 airflow does not negatively impact the laminar flow ofthe ISO 5 heeds despite the fact that the HEPA filters in the ISO 7 room are located partially over the openings to the ISO 5 hoods.

3) Employees were observed pulling solutions from vials and injecting them into IV bags and ...

Read the full 483 (PDF on fda.gov)

Observation 4

Personnel touched equipment or other surfaces located outside of the ISO 5 classified aseptic processing area with gloved hands and then engaged in aseptic processing without changing or sanitizing gloves.

Specifically, on different occasions, employees engaged in the production of sterile drugs in ISO 5 laminar airflow hoods were observed exiting the ISO 5 hood area and touching items in the ISO 7 cleanroom, including a keyboard, telephone, nonsterile IV bag packages, paperwork, a computer monitor, and pushing down discarded nonsterile packaging in the garbage can, and then returning to the ISO 5 area without sanitizing or replacing their gloves.

Observation 5

Materials or supplies were not disinfected prior to entering the aseptic processing areas.

Specifically, employees were observed taking non-sterile IV bags and vials into the ISO 7 room from the pass-through originating in an unclassified room and then putting them directly into the ISO 5 laminar airflow hood without any decontamination step.

Observation 6

Personnel did not disinfect and change gloves frequently enough to prevent contamination.

Specifically, an employee was observed donning sterile gloves and then touching multiple items and performing multiple tasks in the ISO 7 area, including pushing down trash in the trash can, using the telephone, taking multiple items from the pass-through originating in an unclassified room, typing on a keyboard, and using a touchscreen, before putting her hands into the ISO 5 laminar airflow hood to start sterile production without changing her gloves.

Observation 7

Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.

Specifically, gowning for employees involved in sterile drug production in the ISO 5 laminar airflow hoods consists of sterile gloves, non-sterile masks, non-sterile hooded body suits that are taken off and re-used throughout the day, and no eye-covering, resulting in exposed skin around the eyes, despite the fact that the employee's entire upper body must enter the ISO 5 hood to properly produce sterile drug products.

Observation 8

Your facility design allowed the influx of poor quality air into a higher classified area.

Specifically, the pass-through into the ISO 7 cleanroom used to pass all components, containers, and closures for sterile drug production into the cleanroom originates in an unclassified room, has doors that do not seal, has unused screw holes that contain expose particle board inside the pass-through, has rust colored discoloration on the hinges on the ISO 7 side, and has visible dust in a gap between the pass-through and the wall on the ISO 7 side.

colored discoloration on the hinges on the ISO 7 side, and has visible dust in a gap between the pass- through and the wall on the ISO 7 side.

Observation 9

Personnel moved rapidly in the vicinity of open sterile units and instruments, which disrupted the airflow and increased the risk of bringing lesser quality air into the ISO 5 classified aseptic processing area.

Specifically, an employee was observed unfolding a black trash bag and then shaking it in a vigorous manner directly in front of and less than a foot from the work surface ofthe ISO 5 laminar airflow hood being used to produce sterile total parenteral nutrition while ingredient vials and IV bags for production were staged, cleaned and ready for production, and directly in front of and approximately three feet from the work surface ofthe ISO 5 laminar airflow hood being used to produce sterile home infusion systems while production was in progress.

Observation 10

You produced beta-lactam drugs without providing adequate containment and segregation to prevent cross-contamination.

Specifically, multiple sterile penicillin and cephalosporin drugs are produced in the same positive pressure ISO 5 laminar airflow hoods that are used to produce all sterile non-chemotherapeutic drugs, and there is no procedure to specify how spills are to be cleaned.

State board of pharmacy records

State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.